[Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ]. 2019

Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
The Third Clinical Medical School of Guangzhou University of Tranditional Chinese Medicine;Guangzhou 510000, Guangdong Province, China.

OBJECTIVE To explore the effect of Bushen Yanggu Decoction (BYD) on drug resistance and proliferation of human multiple myeloma-resistant KM3/BTZ cells. METHODS Human multidrug-resistant KM3/BTZ cells were established by Bortezomib (BTZ) gradient induction. The effects of commonly used chemotherapeutic drugs and serum containing Bushen Yanggu Decoction (BYD) on the proliferation of KM3 cells and KM3/BTZ cells were detected by MTT assay. RT-qPCR and Western blot were used to detect the expression of Par-4, HSP27 and P-gp genes. Flow cytometry was used to detect cell apoptosis. RESULTS The established KM3/BTZ cells could produce varying degree of resistance to commonly used chemotherapeutic drugs. Among them, the highest resistance index (RI) to BTZ was 20.269. MTT assay showed that the proliferation of KM3/BTZ cells treated with serum containing Bushen Yanggu Decoction was inhibited, and the inhibitory effect increased with the serum concentration incranse of Bushen Yanggu Decoction. The serum containing Bushen Yanggu Decoction could inhibit the proliferation of KM3/BTZ cells, and induce apoptosis, significantly reduce the drug-resistance of KM3/BTZ cells, up-regulate the expression of Par-4, down-regulate the expression of HSP27 and P-gp. CONCLUSIONS Bushen Yanggu Decoction can effectively inhibit the proliferation of KM3/BTZ cells and induce apoptosis. Bushen Yanggu Decoction can effectively reverse the multidrug-resistance of KM3/BTZ cells. The mechanism may be related with the decrease of expression of HSP27 and P-gp and the increase of expression of Par-4.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
October 2007, Zhongguo shi yan xue ye xue za zhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
April 2010, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
March 2009, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
February 2012, Zhongguo shi yan xue ye xue za zhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
June 2004, Chinese medical journal,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
December 2009, Zhongguo shi yan xue ye xue za zhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
October 2004, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
October 2007, Zhongguo shi yan xue ye xue za zhi,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
October 2006, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology,
Yu-Peng Li, and Jian-Guo Zhang, and Zi-Qing Fang, and Xing-Ru Huang, and Xu Chen, and Zhen-Jie Li, and Jian Fang
December 1995, Bailliere's clinical haematology,
Copied contents to your clipboard!